David A. Siegel Relmada Therapeutics, Inc. Put Options Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding RLMD
# of Institutions
49Shares Held
6.3MCall Options Held
0Put Options Held
0-
Acadian Asset Management LLC Boston, MA1.23MShares$1.01 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.21MShares$990,6210.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$470,1170.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$406,0190.03% of portfolio
-
Geode Capital Management, LLC Boston, MA302KShares$247,5440.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $23.5M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...